Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

125.55USD
1 Aug 2014
Price Change (% chg)

$-1.84 (-1.44%)
Prev Close
$127.39
Open
$126.17
Day's High
$127.30
Day's Low
$124.76
Volume
4,543,694
Avg. Vol
2,983,907
52-wk High
$131.24
52-wk Low
$103.31

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the... (more)

Overall

Beta: 0.50
Market Cap (Mil.): $96,689.01
Shares Outstanding (Mil.): 759.00
Dividend: 0.61
Yield (%): 1.92

Financials

  AMGN.O Industry Sector
P/E (TTM): 19.52 35.76 36.20
EPS (TTM): 6.53 -- --
ROI: 9.15 18.79 18.07
ROE: 22.27 19.47 18.86
Search Stocks

Sanofi, Regeneron cholesterol drug may cut heart risk, trial hints

NEW YORK/PARIS - A new drug being developed by Sanofi SA and Regeneron Pharmaceuticals Inc significantly cut cholesterol in nine late-stage clinical trials, the companies said on Wednesday, and provided the first glimpse of its potential to prevent heart attacks and strokes.

30 Jul 2014

Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials

PARIS, July 30 - A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

30 Jul 2014

Amgen to cut up to 2,900 jobs, prepares to introduce new drugs

- Amgen Inc on Tuesday said it would cut up to 15 percent of its work force and close plants in a series of moves aimed at reallocating resources as it prepares to introduce new medicines it hopes will drive future growth.

29 Jul 2014

UPDATE 2-Amgen to cut up to 2,900 jobs, prepares to introduce new drugs

July 29 - Amgen Inc on Tuesday said it would cut up to 15 percent of its work force and close plants in a series of moves aimed at reallocating resources as it prepares to introduce new medicines it hopes will drive future growth.

29 Jul 2014

Amgen 2nd quarter profit rises; announces up to 2,900 job cuts

July 29 - Amgen Inc on Tuesday posted higher-than-expected second-quarter profit in a rebound from a disappointing first quarter, helped by strong sales of its rheumatoid arthritis drug Enbrel, and it significantly raised its full-year earnings forecast.

29 Jul 2014

Amgen growth in Brazil picks up, eyes doubling portfolio by 2020

SAO PAULO - Amgen Inc, the world's biggest biotechnology company, has had a surge in sales in Brazil this year and it plans to double its drug portfolio in the country by the end of the decade, the company's top local executive says.

23 Jul 2014

Amgen growth in Brazil picks up, eyes doubling portfolio by 2020

SAO PAULO - Amgen Inc, the world's biggest biotechnology company, has had a surge in sales in Brazil this year and it plans to double its drug portfolio in the country by the end of the decade, the company's top local executive says.

23 Jul 2014

Bind Therapeutics ends cancer drug partnership with Amgen

- Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

02 Jul 2014

Bind Therapeutics ends cancer drug partnership with Amgen

July 2 - Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

02 Jul 2014

Amgen psoriatic arthritis drug maintains efficacy after 1 yr -study

June 11 - A drug being developed by Amgen Inc for psoriatic arthritis demonstrated sustained effectiveness after a year of treatment with no new safety concerns, according to data from a midstage trial.

11 Jun 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks